Company Summary

SECTOR

Revenue

Employees

1,950

Established

1989

Public

NASDAQ: VRTX

According to our data here at Mergr, Vertex Pharmaceuticals has acquired 3 companies, including 1 in the last 5 years. It has also divested 2 assets.

Vertex Pharmaceuticals’ largest acquisition to date was in 2001, when it acquired Aurora Biosciences for $592M. It’s largest disclosed sale occurred in 2013, when it sold INCIVO to Janssen Pharmaceuticals for $152M. Vertex Pharmaceuticals has acquired in 2 different US states, and 2 countries. The Company’s most targeted sectors include life science (100%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 410 life science companies that have made at least 1 acquisition, 23 have acquired at least 5 companies, and 3 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to Vertex Pharmaceuticals’ M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.